Notícias e Atividades da Akero Therapeutics

Akero Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Akero Therapeutics é uma empresa listada sob o símbolo AKRO (US).

Veja o organograma con seus 16 executivos principais

Biografias mais buscadas da Akero Therapeutics

• Andrew Cheng, Director, President and Chief Executive Officer
• Graham Walmsley, Director
• Jane Henderson, Director

Criar um alerta
para seguir os movimentos de executivos da Akero Therapeutics.

Akero Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Akero Therapeutics

• Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | Akero Therapeutics, Inc.
• Akero Therapeutics to Present at the Jefferies Global Healthcare Conference | Akero Therapeutics, Inc.
• Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 | Akero Therapeutics,
• Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine | Akero Therapeutics, Inc.
• Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Akero Therapeutics, Inc.
• Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 | Akero Therapeutics, Inc.
• Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference | Akero Therapeutics, Inc.
• Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 | Akero Therapeutics, Inc.
• Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Akero Therapeutics, Inc.
• Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Akero Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Akero Therapeutics

• Akero Therapeutics na Wikipedia, Google News e Yahoo Finance
• Akero Therapeutics na LinkedIn, Twitter e YouTube